Memory Enhancement Using Transcranial Alternating Current Stimulation (Memento)

Amsterdam UMC, location VUmc

Status: Begins enrollment this month

Conditions: Alzheimer Disease; Mild Cognitive Impairment

Treatments: Device: Sham tACS at the precuneus region; Device: Gamma (40 Hz) tACS at the precuneus region

Study type: Interventional

Funder types: Other

Identifiers

NCT06202872

20212222

Details and patient eligibility

About

The 32 million Alzheimer's disease (AD) and 69 million prodromal AD patients worldwide contribute to a large economic burden. Effective and safe therapies that slow or prevent the progression from mild cognitive impairment (MCI) to AD are therefore of high priority. Transcranial alternating current stimulation (tACS) is a safe and patient-friendly non-invasive brain stimulation technique that serves as a potential candidate for reducing and/or slowing cognitive impairment. Application of tACS in the gamma frequency range, specifically around 40 Hz, has been studied in patients with AD and MCI due to AD. In these patients, a single session of 40 Hz tACS at the precuneus showed to improve episodic memory and to increase gamma power, as measured with electroencephalography. These findings will be replicated in the current study in patients with MCI due to AD, using magnetoencephalography (MEG) recorded before, during and after tACS. In this way, brain activity and network changes that underlie this improvement in episodic memory can be studied with greater temporal and spatial detail.

Enrollment: 27 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Recent (not more than 6 months ago) amnestic MCI diagnosis, which consensus is obtained in a multidisciplinary meeting after an extended multidisciplinary test battery at the memory clinic, including confirmation of AD pathology with cerebrospinal fluid biomarkers: abnormal p-tau/Aβ42 ratio of > 0.023

Exclusion criteria

• Suffering from serious neurological, psychiatric or somatic comorbidity
• Suffering from epileptic seizures or severe claustrophobia
• Intensive use of psychoactive medication
• Having a cardiac pacemaker, internal cardiac defibrillator or other intracorporeal device that interferes with MEG recordings

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Quadruple Blind

---

27 participants in 2 patient groups

Active tACS

Experimental group

Description:

Gamma (40 Hz) tACS at the precuneus region

Treatment:

Device: Gamma (40 Hz) tACS at the precuneus region

Sham tACS

Sham Comparator group

Description:

Sham tACS at the precuneus region

Treatment:

Device: Sham tACS at the precuneus region